GET DAILY SIGNALSBluejay Diagnostics (BJDX): What the Upcoming Q3 2026 Report May Reveal
Key Takeaways
- Bluejay Diagnostics (BJDX) is expected to report its third-quarter fiscal 2026 results around mid-November 2026.
- As a clinical-stage, pre-revenue medical diagnostics company, the report will center on net loss, cash burn, and balance sheet strength rather than revenue growth.
- The Symphony testing platform and its lead candidate, the IL-6 (interleukin-6) test for sepsis triage, remain subject to U.S. FDA clearance, making regulatory progress a key theme.
- Recent quarterly losses have narrowed on a per-share basis, though the company still generates no product revenue and funds operations primarily through equity and warrant financings.
- Given its micro-cap profile and limited sell-side coverage, investor attention will focus on cash runway and any signs of additional dilution.
- For more context on this ticker, readers can explore its Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- Investors looking for broader market ideas may also want to explore Trending AI Robots.
Earnings Context and Why It Matters
Bluejay Diagnostics is a clinical-stage diagnostics company based in Acton, Massachusetts, developing the Symphony System, a rapid, near-patient testing platform for critical care settings. Because the company has not yet received FDA clearance for its lead product and remains pre-revenue, its quarterly earnings carry a different weight than those of a commercial-stage business. For investors, this report is less about sales and more about how efficiently management is conserving capital while advancing regulatory and clinical milestones. Prior quarters have shown narrowing net losses, but the company's ability to fund continued development without excessive shareholder dilution is the central question heading into the report. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
Analyst coverage of BJDX is limited, and meaningful consensus revenue estimates are not widely available because the company does not yet generate product revenue. The focus, instead, falls on the bottom line and liquidity. In its most recently reported period, the second quarter of fiscal 2026 ended June 30, 2026, the company posted a net loss of approximately $2.3 million and a loss of $1.12 per share. That followed a loss of $1.95 per share in the first quarter and $1.56 per share in the fourth quarter of fiscal 2025. Investors will be watching whether the per-share loss continues to narrow and, more importantly, how much cash remains on the balance sheet relative to the operating burn rate.
Market Reaction and Investor Sentiment
Heading into the third-quarter report, sentiment around BJDX reflects the uncertainty typical of a pre-revenue micro-cap. The stock has historically been volatile around earnings, driven less by operating results than by funding announcements, clinical progress, and broader small-cap risk appetite. Key risk factors include the absence of near-term revenue, the potential need for additional capital raises, and the timing of any regulatory feedback from the FDA. Investors are likely to react most to updates on cash runway and development milestones rather than to the loss figure itself.
Forward Outlook and Key Factors to Monitor
Following the third-quarter report, investors should watch three areas closely. First, the cash position and operating burn rate will indicate how far the company's existing resources can carry it and whether another financing may be needed in the near term.
Second, regulatory and clinical progress on the Symphony IL-6 test for sepsis will be a defining catalyst. Any update on FDA submission timing, study milestones, or manufacturing scale-up could materially shape the investment narrative, given that the platform is the company's core asset.
Third, cost discipline and capital structure matter. With a small team and limited commercial infrastructure, the company's ability to control expenses while advancing development will determine the pace of dilution. Industry dynamics, including demand for rapid near-patient diagnostics in critical care, also provide a longer-term backdrop, though commercialization remains contingent on regulatory approval.
AI Tools in My Analysis Workflow
One resource I turn to regularly for deeper market scans is Tickeron’s AI Screener. It helps me quickly filter for companies based on technical patterns, fundamentals, and performance metrics, which is especially useful when evaluating early-stage names like this one ahead of earnings. The tool surfaces ideas efficiently and supports a more structured approach to tracking developments across the sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for BJDX turns positive, indicating new upward trend
BJDX saw its Momentum Indicator move above the 0 level on November 09, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 102 similar instances where the indicator turned positive. In 87 of the 102 cases, the stock moved higher in the following days. The odds of a move higher are at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BJDX's RSI Oscillator exited the oversold zone, 35 of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 65 of 77 cases where BJDX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for BJDX just turned positive on November 05, 2026. Looking at past instances where BJDX's MACD turned positive, the stock continued to rise in 32 of 39 cases over the following month. The odds of a continued upward trend are 82%.
Following a +19.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where BJDX advanced for three days, in 145 of 182 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BJDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
BJDX broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BJDX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.258) is normal, around the industry mean (4.142). P/E Ratio (-1.035) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. BJDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BJDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices